Drugmaker Roche said its experimental medicine for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy.» Read More
Teva will acquire Allergan's generics unit for $40.5 billion. CNBC's Meg Tirrell takes a look at other potential M&A action in the space.
Chart analyst John Kosar shows how investors can profit from the pullback in oil prices.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
CNBC's Meg Tirrell reports on the FDA approving Regeneron's cholesterol drug Praluent.
Shares of Regeneron were down about 3 percent after the FDA approved Regeneron's cholesterol-lowering drug Praluent on Friday.
CNBC's Meg Tirrell reports on a Glaxo Malaria vaccine for use in Sub-Saharan Africa as it seeks the final steps to approval.
CNBC's Meg Tirrell looks ahead at pharma earnings to come. FMHR traders weigh in on the health care space.
CNBC's Meg Tirrell reports on Biogen's sales growth as the company misses sales estimates.
Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.
Jim Cramer explains why he is watching shares of Biogen after the company lowered its guidance
Hans Bishop, Juno Therapeutics CEO, discusses advances made in immunotherapy to treat cancers and other types of tumors by using the body's immune system to defend itself.
Yossi Pollak, chief executive officer at Sight Diagnostics, explains how computer algorithms make blood testing more efficient.
The world's first malaria vaccine got a green light on Friday from European drugs regulators.
Ebola briefly returned to the headlines this week with a scare at a hospital in New York, but the deadly virus continues to claim victims in West Africa.
Valuation are "very high" in the pharmaceutical sector, Roche CEO Severin Schwan told CNBC on Thursday after the company posted a rise in sales.
CNBC's Meg Tirrell reports on the latest developments in Eli Lilly and Biogen's Alzheimer drugs.
CNBC's Meg Tirrell reports on the highly anticipated trial results out from Eli Lilly and Biogen.
Hedge funds and and a new type of patent troll are using loopholes in patent law for gains, stifling innovation, says author Joseph Gulfo.
CNBC's Meg Tirrell reports on the highly-anticipated data on Eli Lilly's new Alzheimer drug.
Get the best of CNBC in your inbox